Cargando…

A review on exosomes application in clinical trials: perspective, questions, and challenges

BACKGROUND: Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases....

Descripción completa

Detalles Bibliográficos
Autores principales: Rezaie, Jafar, Feghhi, Maryam, Etemadi, Tahereh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483361/
https://www.ncbi.nlm.nih.gov/pubmed/36123730
http://dx.doi.org/10.1186/s12964-022-00959-4
_version_ 1784791654445613056
author Rezaie, Jafar
Feghhi, Maryam
Etemadi, Tahereh
author_facet Rezaie, Jafar
Feghhi, Maryam
Etemadi, Tahereh
author_sort Rezaie, Jafar
collection PubMed
description BACKGROUND: Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases. METHODS: In this review study, we studied numerous articles over the past two decades published on application of exosomes in different diseases as well as on perspective and challenges in this field. RESULTS: The main clinical application of exosomes are using them as a biomarker, cell-free therapeutic agents, drug delivery carriers, basic analysis for exosome kinetics, and cancer vaccine. Different exosomes from human or plant sources are utilized in various clinical trials. Most researchers used exosomes from the circulatory system for biomarker experiments. Mesenchymal stem cells (MSCs) and dendritic cells (DCs) are two widely held cell sources for exosome use. MSCs-derived exosomes are commonly used for inflammation treatment and drug delivery, while DCs-exosomes are used to induce inflammation response in cancer patients. However, the clinical application of exosomes faces various questions and challenges. In addition, translation of exosome-based clinical trials is required to conform to specific good manufacturing practices (GMP). In this review, we summarize exosomes in the clinical trials according to the type of application and disease. We also address the main questions and challenges regarding exosome kinetics and clinical applications. CONCLUSIONS: Exosomes are promising platforms for treatment of many diseases in clinical trials. This exciting field is developing hastily, understanding of the underlying mechanisms that direct the various observed roles of exosomes remains far from complete and needs further multidisciplinary research in working with these small vesicles. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00959-4.
format Online
Article
Text
id pubmed-9483361
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94833612022-09-19 A review on exosomes application in clinical trials: perspective, questions, and challenges Rezaie, Jafar Feghhi, Maryam Etemadi, Tahereh Cell Commun Signal Review BACKGROUND: Exosomes are progressively known as significant mediators of cell-to-cell communication. They convey active biomolecules to target cells and have vital functions in several physiological and pathological processes, and show substantial promise as novel treatment strategies for diseases. METHODS: In this review study, we studied numerous articles over the past two decades published on application of exosomes in different diseases as well as on perspective and challenges in this field. RESULTS: The main clinical application of exosomes are using them as a biomarker, cell-free therapeutic agents, drug delivery carriers, basic analysis for exosome kinetics, and cancer vaccine. Different exosomes from human or plant sources are utilized in various clinical trials. Most researchers used exosomes from the circulatory system for biomarker experiments. Mesenchymal stem cells (MSCs) and dendritic cells (DCs) are two widely held cell sources for exosome use. MSCs-derived exosomes are commonly used for inflammation treatment and drug delivery, while DCs-exosomes are used to induce inflammation response in cancer patients. However, the clinical application of exosomes faces various questions and challenges. In addition, translation of exosome-based clinical trials is required to conform to specific good manufacturing practices (GMP). In this review, we summarize exosomes in the clinical trials according to the type of application and disease. We also address the main questions and challenges regarding exosome kinetics and clinical applications. CONCLUSIONS: Exosomes are promising platforms for treatment of many diseases in clinical trials. This exciting field is developing hastily, understanding of the underlying mechanisms that direct the various observed roles of exosomes remains far from complete and needs further multidisciplinary research in working with these small vesicles. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-022-00959-4. BioMed Central 2022-09-19 /pmc/articles/PMC9483361/ /pubmed/36123730 http://dx.doi.org/10.1186/s12964-022-00959-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Rezaie, Jafar
Feghhi, Maryam
Etemadi, Tahereh
A review on exosomes application in clinical trials: perspective, questions, and challenges
title A review on exosomes application in clinical trials: perspective, questions, and challenges
title_full A review on exosomes application in clinical trials: perspective, questions, and challenges
title_fullStr A review on exosomes application in clinical trials: perspective, questions, and challenges
title_full_unstemmed A review on exosomes application in clinical trials: perspective, questions, and challenges
title_short A review on exosomes application in clinical trials: perspective, questions, and challenges
title_sort review on exosomes application in clinical trials: perspective, questions, and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483361/
https://www.ncbi.nlm.nih.gov/pubmed/36123730
http://dx.doi.org/10.1186/s12964-022-00959-4
work_keys_str_mv AT rezaiejafar areviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges
AT feghhimaryam areviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges
AT etemaditahereh areviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges
AT rezaiejafar reviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges
AT feghhimaryam reviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges
AT etemaditahereh reviewonexosomesapplicationinclinicaltrialsperspectivequestionsandchallenges